Durham, NC (PRWEB) August 31, 2012
The Society for Translational Oncology (STO) is pleased to announce that Dr. Richard L. Schilsky, M.D., Professor of Medicine and Section Chief of Hematology/Oncology at the University of Chicago Department of Medicine, has been named recipient of the 2012 Bob Pinedo Cancer Care Prize. The award recognizes Dr. Schilsky's clinical and research leadership in the areas of gastrointestinal cancers and cancer pharmacology coupled with his compassionate care of cancer patients.
This year's Pinedo Prize of $50,000 will be presented at the Third Annual STO meeting, to be hosted by UNC Lineberger Comprehensive Cancer Center at the Rizzo Center in Chapel Hill, N.C., October 20-21, 2012. Dr. Schilsky will deliver the keynote lecture, “Publicly Funded Clinical Trials and the Future of Cancer Care”. The 2012 Pinedo Prize Lecture will be published by The Oncologist, STO's official journal.
An internationally recognized expert on gastrointestinal malignancies, Dr. Schilsky is also a leader in the development and evaluation of new treatments for cancer. He is past Chairman of the Cancer and Leukemia Group B (CALGB), a national cancer clinical trials group sponsored by the National Cancer Institute and former chair of the Board of Scientific Advisors of the National Cancer Institute and of the Oncology Drugs Advisory Committee of FDA.
Dr. Schilsky is a past president of the American Society of Clinical Oncology and was recently named an ASCO Fellow. He is an officer of the Board of Directors of the Conquer Cancer Foundation of ASCO. Among his many peer-reviewed activities, Dr. Schilsky is senior associate editor of Molecular Oncology, associate editor of the Journal of the National Cancer Institute and of Seminars in Oncology, and a member of the editorial boards of The Oncologist, Clinical Cancer Research, and Cancer Prevention Research.
“Dr. Schilsky is richly deserving of being named this year's Pinedo Prize winner," commented Prof. Patrick G. Johnston, co-chairman of STO. "As a Clinician Scientist, he combines the ideal of compassionate patient care with a relentless search for clinical improvement. He has also played a uniquely important role in the design and conduct of high-quality research trials that help in translating new scientific evidence into effective and efficient care for patients with cancer.”
The Pinedo Cancer Care Prize honors Professor H.M. (Bob) Pinedo, founder of the VU University Medical Center (VUmc) Cancer Center Amsterdam (CCA), who weds world-class cancer research with a devotion to his patients and their families. In the past six years, The Bob Pinedo Cancer Care Prize has been awarded to:
- Bruce Chabner, MD – Massachusetts General Hospital Cancer Center
- Joseph Bertino, MD – The Cancer Institute of New Jersey
- Bob Löwenberg, MD – Erasmus University Medical Centre
- Richard O’Reilly, MD – Memorial Sloan-Kettering Cancer Center
- José Baselga, MD, PhD – Massachusetts General Hospital Cancer Center
- Gabriel N. Hortobágyi, MD – The University of Texas MD Anderson Cancer Center
Nominations for the 2013 Pinedo Prize will be received by Professor Patrick Johnston, Chairman, Nominating Committee: Pinedo(dot)Prize(at)STO-online(dot)org until February 1, 2013. All nominations will be evaluated by an international jury.
# # #
About the Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: http://www.sto-online.org.
About The Oncologist
Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its eighteenth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit: http://www.theoncologist.com.
About the University of Chicago Medicine
When the University of Chicago Medical Center opened its doors to the community in fall 1927, it had two clinical departments: medicine and surgery. Since then, the medical campus has grown to include 60 adult and 44 pediatric specialties. The Medical Center ranks among the best in the country in cancer treatment, digestive disorders, and many other specialties according to various surveys. University of Chicago physician-scientists performed the first organ transplant and the first bone marrow transplant in animal models, the first successful living-donor liver transplant, the first hormone therapy for cancer, and the first successful application of cancer chemotherapy. Its researchers discovered REM sleep and were the first to describe several of the sleep stages. Twelve winners of the Nobel Prize have been affiliated with the University of Chicago Medicine.